TIPIN depletion leads to apoptosis in breast cancer cells

Baldeyron, Céline; Brisson, Amélie; Tesson, Bruno; Némati, Fariba; Koundrioukoff, Stéphane; Saliba, Élie; Koning, Leanne de; Martel, Elise; Ye, Mengliang; Rigaill, Guillem; Meseure, Didier; André, Nathalie; Gentien, David; Decaudin, Didier; Debatisse, Michèlle; Depil, Stéphane; Cruzalegui, Francisco; Pierre, Alain St.; Roman-Roman, Sergio; Tucker, Gordon C.; Dubois, Thierry

doi:10.1016/j.molonc.2015.04.010

Cited by 19 publications

(27 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our cohort, comprising 35 luminal A (LA: ER + /HER2 − ), 40 luminal B (LB: ER + / HER2 + ), 46 TNBC (ER − /PR − / HER2 + ), 33 ER − /PR − /HER2 + , and 18 normal breast tissues, has been described elsewhere . The RNA microarray (Affymetrix U133 plus 2.0, Paris, France) results have also been reported elsewhere …”

Section: Methodsmentioning

confidence: 99%

“…Cells were cultured as previously described . BT‐474, T‐47D, MDA‐MB‐468, and ZR75‐1 cells were maintained in RPMI‐1640 (Life Technologies) supplemented with 10% (vol/vol) fetal bovine serum (FBS; Life Technologies, Courtaboeuf, France), 100 U/mL penicillin, and 100 µg/mL streptomycin (P/S; Life Technologies).…”

Section: Methodsmentioning

confidence: 99%

“…Cells were transfected with siRNAs as previously described . Cells were seeded into 6‐ or 96‐well plates at a density determined on the growth rate of each cell line (Table ).…”

Section: Methodsmentioning

confidence: 99%

“…22,23 The RNA microarray (Affymetrix U133 plus 2.0, Paris, France) results have also been reported elsewhere. [22][23][24][25] The TCGA breast invasive carcinoma (TCGA-BRCA) cohort is publicly available. 26 The RNA-SeqV2 Level 3 data (Jan 2015) were downloaded from the TCGA Research Network (http://cancergenome.nih.gov/) and integrated into a platform in knowledge data integration (KDI) at Institut Curie (https:// bioinfo-portal.curie.fr).…”

Section: Human Samples and Microarray Datamentioning

confidence: 99%

“…Cells were cultured as previously described. [22][23][24][25]29 BT-474, T-47D, MDA-MB-468, and ZR75-1 cells were maintained in RPMI-1640 (Life Technologies) supplemented with 10% (vol/vol) fetal bovine serum (FBS; Life Technologies, Courtaboeuf, France), 100 U/mL penicillin, and 100 µg/mL streptomycin (P/S; Life Technologies). The same media complemented with 1.5 g/L sodium bicarbonate (Life Technologies), 10 mmol/L HEPES (Life Technologies), and 1 mmol/L sodium pyruvate (Life Technologies) was used for HCC1143, HCC1569, HCC1954, HCC38, and HCC70 cells.…”

Section: Cell Lines Cell Authentication and Cell Culturementioning

confidence: 99%

See 4 more Smart Citations

LRP8 is overexpressed in estrogen‐negative breast cancers and a potential target for these tumors

et al. 2018

Self Cite

View full text Add to dashboard Cite

Triple‐negative breast cancer (TNBC) is the breast cancer subtype with the worst prognosis. New treatments improving the survival of TNBC patients are, therefore, urgently required. We performed a transcriptome microarray analysis to identify new treatment targets for TNBC. We found that low‐density lipoprotein receptor‐related protein 8 (LRP8) was more strongly expressed in estrogen receptor‐negative breast tumors, including TNBCs and those overexpressing HER2, than in luminal breast tumors and normal breast tissues. LRP8 depletion decreased cell proliferation more efficiently in estrogen receptor‐negative breast cancer cell lines: TNBC and HER2 overexpressing cell lines. We next focused on TNBC cells for which targeted therapies are not available. LRP8 depletion induced an arrest of the cell cycle progression in G1 phase and programmed cell death. We also found that LRP8 is required for anchorage‐independent growth in vitro, and that its depletion in vivo slowed tumor growth in a xenograft model. Our findings suggest that new approaches targeting LRP8 may constitute promising treatments for hormone‐negative breast cancers, those overexpressing HER2 and TNBCs.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

“…Cells were transfected with siRNAs as previously described . Cells were seeded into 6‐ or 96‐well plates at a density determined on the growth rate of each cell line (Table ).…”

Section: Methodsmentioning

confidence: 99%

Section: Human Samples and Microarray Datamentioning

confidence: 99%

Section: Cell Lines Cell Authentication and Cell Culturementioning

confidence: 99%

See 3 more Smart Citations

LRP8 is overexpressed in estrogen‐negative breast cancers and a potential target for these tumors

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

Protein arginine methyltransferase 5: A novel therapeutic target for triple‐negative breast cancers

et al. 2019

Self Cite

View full text Add to dashboard Cite

TNBC is a highly heterogeneous and aggressive breast cancer subtype associated with high relapse rates, and for which no targeted therapy yet exists. Protein arginine methyltransferase 5 (PRMT5), an enzyme which catalyzes the methylation of arginines on histone and non‐histone proteins, has recently emerged as a putative target for cancer therapy. Potent and specific PRMT5 inhibitors have been developed, but the therapeutic efficacy of PRMT5 targeting in TNBC has not yet been demonstrated. Here, we examine the expression of PRMT5 in a human breast cancer cohort obtained from the Institut Curie, and evaluate the therapeutic potential of pharmacological inhibition of PRMT5 in TNBC. We find that PRMT5 mRNA and protein are expressed at comparable levels in TNBC, luminal breast tumors, and healthy mammary tissues. However, immunohistochemistry analyses reveal that PRMT5 is differentially localized in TNBC compared to other breast cancer subtypes and to normal breast tissues. PRMT5 is heterogeneously expressed in TNBC and high PRMT5 expression correlates with poor prognosis within this breast cancer subtype. Using the small‐molecule inhibitor EPZ015666, we show that PRMT5 inhibition impairs cell proliferation in a subset of TNBC cell lines. PRMT5 inhibition triggers apoptosis, regulates cell cycle progression and decreases mammosphere formation. Furthermore, EPZ015666 administration to a patient‐derived xenograft model of TNBC significantly deters tumor progression. Finally, we reveal potentiation between EGFR and PRMT5 targeting, suggestive of a beneficial combination therapy. Our findings highlight a distinctive subcellular localization of PRMT5 in TNBC, and uphold PRMT5 targeting, alone or in combination, as a relevant treatment strategy for a subset of TNBC.

show abstract

Discovery of WS-384, a first-in-class dual LSD1 and DCN1-UBC12 protein-protein interaction inhibitor for the treatment of non-small cell lung cancer

Li,

Ma,

Wang

et al. 2024

Biomedicine & Pharmacotherapy

View full text Add to dashboard Cite

TIPIN depletion leads to apoptosis in breast cancer cells

Cited by 19 publications

References 71 publications

LRP8 is overexpressed in estrogen‐negative breast cancers and a potential target for these tumors

LRP8 is overexpressed in estrogen‐negative breast cancers and a potential target for these tumors

Protein arginine methyltransferase 5: A novel therapeutic target for triple‐negative breast cancers

Discovery of WS-384, a first-in-class dual LSD1 and DCN1-UBC12 protein-protein interaction inhibitor for the treatment of non-small cell lung cancer

Contact Info

Product

Resources

About